Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuferon + Ribavirin in HCV Genotype 1
NCT00115908Phase 2Completed
- Sponsor
- Human Genome Sciences
- Start
- May 2005
- Primary completion
- May 2007
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of albinterferon alfa-2b in hepatitis C (HCV) (4 arms), sponsored by Human Genome Sciences. Primary endpoint: Sustained Virologic Response. Started May 2005; status: completed.
02
Drugs
albinterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00115908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115908.